GUIDED THERAPEUTICS INC Form 8-K May 01, 2013	
SECURITIES AND EXCHANGE COMMISSION	
Washington, D.C. 20549	
FORM 8-K	
CURRENT REPORT	
Pursuant to Section 13 or 15(d) of the	
Securities Exchange Act of 1934	
Date of Report (Date of Earliest Event) May 1, 2013; (May 1, 2013)	
GUIDED THERAPEUTICS, INC.	
(Exact Name of Registrant as Specified in Its Charter)	

0-22179

(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)

Delaware

58-2029543

Incorporation)

5835 Peachtree Corners East, Suite D	30092
Norcross, Georgia	
(Address of Principal Executive Offices)	(Zip Code)
Registrant's Telephone Number, Includin	g Area Code: (770) 242-8723
Check the appropriate box below if the Fe the registrant under any of the following	orm 8-K filing is intended to simultaneously satisfy the filing obligation of provisions:
[] Written communications pursuant to	Rule 425 under the Securities Act (17 CFR 230.425)
[] Soliciting material pursuant to Rule 1	4a-12 under the Exchange Act (17 CFR 240.14a-12)
[] Pre-commencement communications	pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[] Pre-commencement communications	pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### **Section 7.01 (Regulation FD Disclosure)**

On May 1, 2013, the registrant publicly issued a press release announcing that the LuViva® Advanced Cervical Scan's clinical trial results were to be published in the Journal, *Gynecologic Oncology* as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

#### **Number** Exhibit

99.1 Press Release dated May 1, 2013

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **GUIDED THERAPEUTICS, INC.**

By: <u>/s/ Mark L. Faupel, Ph.D.</u>
Mark L. Faupel, Ph.D.
CEO & President

Date: May 1, 2013

2